Viking Therapeutics, Inc.
VKTX
Updated: 24/09/2026, 01:29:08
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
No summaries found.
- Share price
- $41.65
- Market cap
- $4.86B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Brian Lian
- Employees
- 65
- IPO date
- 28/04/2015
- Beta
- 0.679
- Last dividend
- $0.00
- Day range
- $37.73 – $43.10
- 52-week range
- $24.78 – $43.15
- 1-day performance
- 1.96%
- 1-year performance
- 68.08%
- Current drawdown (1Y)
- -3.48%
- CIK
- 0001607678
- CUSIP
- 92686J106
- ISIN
- US92686J1060
- Created
- 07/12/2025, 14:58:36
- Last update
- 24/09/2026, 01:29:08
Track Viking Therapeutics, Inc. with an AI analyst
See which prediction-market events move VKTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Is Viking Therapeutics Stock Going to $100?
The Motley Fool • STOCK • 12/06/2026, 03:15:00
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.
PRNewsWire • STOCK • 11/06/2026, 09:05:00
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks Investment Research • STOCK • 10/06/2026, 20:50:18
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Zacks Investment Research • STOCK • 04/06/2026, 20:45:30
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 04/06/2026, 17:32:55
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Zacks Investment Research • STOCK • 28/05/2026, 20:46:05
Don't Buy Viking Therapeutics Stock Until You Read This
The Motley Fool • STOCK • 25/05/2026, 22:00:00
Viking Therapeutics to Participate at Upcoming Investor Conferences
PRNewsWire • STOCK • 21/05/2026, 09:05:00
Viking Therapeutics: Market Betting On Big Upside Through 2030
Seeking Alpha • STOCK • 05/05/2026, 14:00:22
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge
MarketBeat • STOCK • 01/05/2026, 12:45:56
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Zacks Investment Research • STOCK • 30/04/2026, 14:31:37
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 30/04/2026, 05:01:34